Sodium Bicarbonate Associated With Enhanced GVL Effect in AML Following Allo-HSCT
Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.
Diagnosis & Disease Information
Combination Sitagliptin, Tacrolimus, Sirolimus for Prophylaxis of Acute Graft-vs-Host-Disease
Investigators aimed to determine whether DPP-4 inhibition reduces the incidence of acute graft-vs-host disease among patients receiving allogeneic HSCT.
Reduced-Intensity Conditioning May Not Improve Post Allogeneic HSCT Outcomes in AML
A sequenced reduced-intensity conditioning regimen may not improve outcomes for patients with acute myeloblastic leukemia and myelodysplasia after allogeneic stem cell transplantation.
Uncertainties Surround Optimal Dosing of Cytarabine in AML
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
Outcomes of Adding a Fourth Chemotherapy Course in AML
For patients with acute myeloid leukemia, a total of 4 courses of chemotherapy may improve relapse rates but not overall survival, compared with 3 total courses of treatment.
PARP Inhibition Associated With Increased Risk for Secondary MDS, AML
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Oral Azacitidine to Improve Survival in First-Remission Acute Myeloid Leukemia
Maintenance therapy with oral azacitidine leads to longer overall survival in older patients with acute myeloid leukemia.
Improvements Seen in Allogeneic Stem Cell Transplantation-Related Mortality
Experts assessed mortality rates linked to allogeneic stem cell transplantation in the past 40 years using data from the European Society for Blood and Marrow Transplantation registry.
Integrated Palliative, Oncology Care Improves Quality of Life in Acute Myeloid Leukemia
Investigators assessed the effectiveness of integrated palliative and oncology care on end-of-life outcomes in patients with acute myeloid leukemia.
Azacitidine vs Decitabine in Unfit, Newly Diagnosed Acute Myeloid Leukemia
Investigators compared clinical outcomes between unfit patients with newly diagnosed AML who were treated with either azacitidine or decitabine.
- Loading...
Loading...
Next post in ASH 2020 AML In-depth
Loading... 
Loading...